Iodine-131-radiolabeled tumor necrosis therapy (TNT) has received marketing approval for lung cancer treatment in the People’s Republic of China, according to biopharmaceutical developer Peregrine Pharmaceuticals and its Chinese partner, MediPharm Biotech. I-131-labeled TNT was approved for the treatment of stage III and stage IV advanced lung cancer through either intravenous or intratumoral administration.
Prior to market launch, however, the State Food and Drug Administration (SFDA) of China must inspect and approve the manufacturing facility that will manufacture the TNT monoclonal antibody, according to Peregrine of Tustin, CA. The timing and specific requirements of this process are uncertain, Peregrine said.
By AuntMinnie.com staff writersAugust 13, 2003
Related Reading
Peregrine, Affitech team up, June 18, 2003
Peregrine regains Nasdaq compliance, June 12, 2003
Peregrine, Schering team up, January 7, 2003
Peregrine begins Nasdaq grace period, August 22, 2002
Copyright © 2003 AuntMinnie.com
